Manzo Pharmaceuticals, Inc.
MNZO
$0.00
$0.000.00%
OTC PK
| 09/30/2005 | 06/30/2005 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 95.02% | -62.73% | |||
| Gross Profit | -95.02% | 62.73% | |||
| SG&A Expenses | -41.93% | -11.15% | |||
| Depreciation & Amortization | -47.85% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.05% | -16.84% | |||
| Operating Income | 31.05% | 16.84% | |||
| Income Before Tax | 4.30% | -111.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.30% | -111.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.30% | -111.34% | |||
| EBIT | 31.05% | 16.84% | |||
| EBITDA | 33.00% | 14.51% | |||
| EPS Basic | 35.15% | -111.14% | |||
| Normalized Basic EPS | 44.32% | -180.62% | |||
| EPS Diluted | 35.92% | -112.43% | |||
| Normalized Diluted EPS | 44.36% | -187.10% | |||
| Average Basic Shares Outstanding | 47.58% | 1.75% | |||
| Average Diluted Shares Outstanding | 47.66% | -5.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||